Capitalised terms in this announcement carry the same definitions as in prior announcements in relation to the Fundraising.
Verici Dx plc, a developer of advanced clinical diagnostics for organ transplant, announces the result of the Restricted Offer made to its shareholders, who returned a valid application form to subscribe for Verici Dx Ordinary Shares of £0.001 each (“Verici Shares”) at the Issue Price, being 20 pence per share (the “Restricted Offer”).
The Restricted Offer for up to £0.5 million was significantly oversubscribed as expected.
The Placing, Subscription and Restricted Offer have, in aggregate, raised £14.5 million through the issue of a total of 72,500,000 new Ordinary Shares at the Issue Price.
The allotment and issue of Verici Dx Shares in connection with the Restricted Offer remains conditional upon, among other things, Admission, which is expected to take place on 3 November.
Applicants to the Restricted Offer can confirm their final allotment of shares by contacting the helpline on 0371 664 0321. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. The helpline is open between 9.00 a.m. and 5.30 p.m., Monday to Friday excluding public holidays in England and Wales. Different charges may apply to calls from mobile telephones and calls may be recorded and randomly monitored for security and training purposes. The helpline cannot provide advice on the merits of the Proposals nor give any financial, legal or tax advice.
Full details of the Fundraising will be contained in the Verici Dx Admission Document, which will be made available shortly before Admission at www.vericidx.com
Sara Barrington, CEO
Julian Baines, Chairman
Via Walbrook PR
N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Kailey Aliyar / Tom Salvesen
Tel: 020 7496 3000
Walbrook PR Limited
Paul McManus / Sam Allen
Tel: 020 7933 8780 or email@example.com
Mob: 07980 541 893 / 07748 651 727